Navigation Links
One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study
Date:10/27/2008

14, patients receiving golimumab 50 mg and 100 mg achieved a mean change of 6.53 and 7.85 scores, respectively, in PCS compared with a mean change of 0.63 among patients receiving placebo (P < 0.001). At six months, these results improved to mean changes of 7.42 and 8.22 in the respective treatment groups, compared with a mean improvement of 0.67 in the placebo group (P < 0.001). Also at week 14, patients receiving golimumab 50 mg achieved a mean change of 2.79 in MCS, while patients receiving golimumab 100 mg achieved a mean change of 3.56, compared with a mean change of 0.40 in patients treated with placebo (P < 0.05). At six months, patients receiving golimumab 50 mg and 100 mg achieved a mean change of 3.37 and 4.29, respectively, compared with 0.60 in placebo-treated patients (P < 0.05).

Self-reported productivity was measured on a Visual Analog Scale (VAS), a tool used to assess the patients' daily productivity at work, school or home. Patients receiving golimumab 50 mg and 100 mg experienced improvements in self-reported productivity, both at 16 and 24 weeks, while patients receiving placebo reported no change in their productivity at 16 weeks and a decrease in productivity at 24 weeks. Additionally, caregivers of golimumab-treated patients experienced a reduction of time lost from work through week 24, compared with caregivers of patients treated with placebo.

Nail, Enthesitis and Dactylitis Response

In patients with nail involvement or enthesitis at baseline, both golimumab treatment groups experienced improvements in psoriatic nail changes and enthesitis, as measured by the Nail Psoriasis Severity Index (NAPSI) and the psoriatic arthritis-modified Maastricht Ankylosing Spondylitis Enthesitis Score (MASES), respectively. In patients with dactylitis at baseline, both golimumab dose groups also experienced improvements in dactylitis, though the changes were not statistically significant with the 50 mg dose. Enthesitis, an inflammation of
'/>"/>

SOURCE Centocor
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Phase 3 studies show golimumab significantly improved signs and symptoms of rheumatoid arthritis
2. Medarex Receives Milestone Payment for Submission of Regulatory Application Requesting Approval of Golimumab (CNTO 148) in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
3. Centocor, Inc. and Schering-Plough Submit Application Requesting Approval of Golimumab in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
4. In-Room Computers and Wall-Mounted Proximity Systems Computer WorkStations Deliver Increased Efficiency; Improved Patient Care
5. Finesse Solutions Launches Improved E-Store for Sensors and Transmitters
6. Kelly Osbourne and International Health Groups Call for Improved Education on Choices and Usage of Contraception
7. Enobia Pharma Presents PreClinical Data Showing ENB-0040 Significantly Improved Survival and Healed Skeletal Manifestations of Severe Hypophosphatasia in Mice
8. Improved culture system for hepatitis C virus infection
9. Pharmacy Students Taught Improved Medication Adherence and Holistic Health Services Through Program Incorporating InforMedixs Med-eXpert(TM) System
10. Sensitivity Enhancements to Monograms Trofile(TM) Assay Demonstrate Improved Power to Select Patients for CCR5 Antagonist Therapy
11. China Kangtai Cactus Biotech Announces Improved Milk Production in Cows From Companys Cactus Cattle Feed
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... 2015  Prima Biomed Ltd. (NASDAQ: PBMD ) ... become a leader in the development of immunotherapeutic products ... final CVac data from the Phase II CAN-003 ovarian ... a clinically meaningful improvement in Overall Survival ("OS") over ... In the group of second remission patients (n=20), ...
(Date:5/21/2015)... , May 21, 2015  The EveryLife Foundation ... (R-UT) and Amy Klobuchar (D-MN) ... Accelerating Cures & Treatments, or OPEN ACT. ... patient advocacy organizations, this bipartisan legislation promises to ... medicines to rare disease patients by incentivizing drug ...
(Date:5/21/2015)... Worms, Germany (PRWEB) May 21, 2015 ... announces that its manufacturing facility in Worms, Germany ... EXCiPACTâ„¢, an independent subsidiary of the International Pharmaceutical ... three Grace facilities that produce its SYLOID® FP ... now received GMP certification, following the Curtis Bay, ...
(Date:5/21/2015)... , May 21, 2015  CytRx Corporation (NASDAQ: ... company specializing in oncology, today announced positive updated ... with aldoxorubicin for the treatment of unresectable glioblastoma ...  The open-label, multisite trial is designed to investigate ... patients whose tumors have progressed following prior treatment ...
Breaking Biology Technology:Correction Continues after Big Move - BrokerBank Securities, Inc. 2Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7
... ISOT ) ("IsoTis"), an orthobiologics company, today announced that,it ... US Food and Drug,Administration ("FDA"), clearing the Accell Family ... medical devices. The Accell Family of Products includes ... well as a new Accell product that is not,currently ...
... CEL-SCI Corporation,(Amex: CVM ), will present ... South Carolina. On August 20, 2007 at ... give a 25-minute presentation regarding CEL-SCI,s late stage,cancer ... a question,and answer session following the presentation and ...
... and Increased Space, Poised for Market Launch, KIRKLAND, ... developing innovative devices for the treatment of arterial,disease, today ... Joseph W.,Rafferty, and has started building its sales team ... PV(TM) Atherectomy System. Recently Pathway moved from its ...
Cached Biology Technology:IsoTis Receives FDA Clearance for Accell Family of Products 2IsoTis Receives FDA Clearance for Accell Family of Products 3IsoTis Receives FDA Clearance for Accell Family of Products 4CEL-SCI to Present at the Noble Financial Conference 2Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth 2
(Date:4/27/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market, announces that its Wocket® Smart ... week of May, 2015 and will be fulfilling all ... Gino Pereira , Chief Executive Officer said, ... Wocket® enters the consumer market. We would like to ...
(Date:4/20/2015)... 2015 The announcement comes as ... Records Management (GRM), Ireland,s foremost records ... Having built up an impressive track record of clients within ... within the records management sector in Dubai ... GCC staffbase and employ a further eight staff members at ...
(Date:4/13/2015)... According to a recently ... & Opportunities, 2020", the global biometrics market is ... till 2020. The biometrics market is garnering attention ... review of biometric management systems. The constant development ... greater efficiency, are resulting in increasing installation of ...
Breaking Biology News(10 mins):Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2
... orchestrated by a spectrum of signals from hormones within ... cytokinins originate in the roots of plants, and their ... leaves stimulates plant development. Though these phytohormones have been ... their transportation within plants was previously poorly understood. ...
... PA, February 20, 2014 Schizophrenia has long been known ... of the population. Researchers have been following two paths in ... they studied common gene variants that, individually, only increase the ... likelihood of developing schizophrenia from a 10 out of a ...
... fruits and vegetables are associated with higher Body Mass ... households, according to American University researchers in the journal ... significant, association between the prices of fruit and vegetables ... lead author and assistant professor of public administration and ...
Cached Biology News:Roots to shoots: Hormone transport in plants deciphered 2Gathering the clues to rare gene variants contributing to schizophrenia 2High cost of fruits, vegetables linked to higher body fat in young children 2
Edited by D.M. Gersten (1996) Provides comprehensive descriptions of the techniques available for analytical gel electrophoresis of proteins and offers clear step-by-step protocols for all of the m...
The Protein Kinase Factsbooks (2 Volume Set)...
... Edited by John M. Walker (1996) ... successful analytical techniques for studying proteins ... protocol contains detailed, step-by-step instruction, timesaving ... and comprehensive lists of reagents and ...
All serum is collected from U.S.D.A. fryers and broilers. Pricing: $15/unit for 1 - 10 units; $12/unit for 11 - 50 units...
Biology Products: